Last reviewed · How we verify
Intradermal HBV 1 course — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Intradermal HBV 1 course (Intradermal HBV 1 course) — The HIV Netherlands Australia Thailand Research Collaboration.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intradermal HBV 1 course TARGET | Intradermal HBV 1 course | The HIV Netherlands Australia Thailand Research Collaboration | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intradermal HBV 1 course CI watch — RSS
- Intradermal HBV 1 course CI watch — Atom
- Intradermal HBV 1 course CI watch — JSON
- Intradermal HBV 1 course alone — RSS
Cite this brief
Drug Landscape (2026). Intradermal HBV 1 course — Competitive Intelligence Brief. https://druglandscape.com/ci/intradermal-hbv-1-course. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab